(Q33319625)

25 July 2017

1 reference

title

Pharmacotherapy for social anxiety disorder: a systematic review (English)

1 reference

25 July 2017

0 references

1 reference

social anxiety disorder

1 reference

3

1 reference

25 July 2017

Jonathan C Ipser

1

1 reference

25 July 2017

Catherine M Kariuki

series ordinal

2

1 reference

25 July 2017

publication date

1 February 2008

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

25 July 2017

published in

1 reference

25 July 2017

volume

8

1 reference

25 July 2017

issue

2

1 reference

25 July 2017

page(s)

235-257

1 reference

Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Impact of generalized social anxiety disorder in managed care

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

A direct-interview family study of generalized social phobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Social phobia in a population-based female adolescent twin sample: co-morbidity and associated suicide-related symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Psychological and pharmacological treatments of social phobia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Drug treatment of social phobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Pharmacotherapy of Social Phobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Efficacy of olanzapine in social anxiety disorder: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Social phobia. Review of a neglected anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Pharmacotherapy of social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Pharmacological treatment of social anxiety disorder: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Psychometric properties of the Liebowitz Social Anxiety Scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Quantitative analysis of sponsorship bias in economic studies of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Treatment of social phobia with gabapentin: a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Social phobia: the clinical efficacy and tolerability of the monoamine oxidase -A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Paroxetine for social anxiety and alcohol use in dual-diagnosed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Discontinuation of clonazepam in the treatment of social phobia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Levetiracetam in social phobia: a placebo controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

ECNP Consensus Meeting, March 2003. Guidelines for the investigation of efficacy in social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

How much do sample characteristics affect the effect size? An investigation of studies testing the treatment effects for social phobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Citalopram treatment of social anxiety disorder with comorbid major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Social phobia: long-term treatment outcome and prediction of response--a moclobemide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Co-occurrence of 12-month mood and anxiety disorders and personality disorders in the US: results from the national epidemiologic survey on alcohol and related conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Associations in the course of personality disorders and Axis I disorders over time

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Pharmacotherapy of social anxiety disorder at the turn of the millennium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Controlled Evaluation of Intravenous Drugs in the Specific Desensitization of Phobias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Integrating pharmacotherapy and psychotherapy in the management of anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Phenelzine efficacy in refractory social anxiety disorder: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Flooding with brevital in the treatment of agoraphobia: Countereffective?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Behaviour therapy and benzodiazepines: allies or antagonists?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

Treatment of social phobia with clonazepam and placebo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.2.235

21 January 2018

Identifiers

DOI

10.1586/14737175.8.2.235

1 reference

25 July 2017

1 reference